Maria J Lizardo-Thiebaud, Eduardo Cervantes-Alvarez, Nathaly Limon-de la Rosa, Farid Tejeda-Dominguez, Mildred Palacios-Jimenez, Osvely Méndez-Guerrero, Marco Delaye-Martinez, Fatima Rodriguez-Alvarez, Beatriz Romero-Morales, Wei-Hui Liu, Christene A Huang, David Kershenobich, Nalu Navarro-Alvarez
Journal: Seminars in liver disease 2020;40(3):321-330
PMID: 32886936
Liver injury can result from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection with more than one-third of COVID-19 patients exhibiting elevated liver enzymes. Microvesicular steatosis, inflammation, vascular congestion, and thrombosis in the liver have been described in autopsy samples from COVID-19 patients. Several factors, including direct cytopathic effect of the virus, immune-mediated collateral damage, or an exacerbation of preexisting liver disease may contribute to liver pathology in COVID-19. Due to its immunological functions, the liver is an organ likely to participate in the viral response against SARS-CoV-2 and this may predispose it to injury. A better understanding of the mechanism contributing to liver injury is needed to develop and implement early measures to prevent serious liver damage in patients suffering from COVID-19. This review summarizes current reports of SARS-CoV-2 with an emphasis on how direct infection and subsequent severe inflammatory response may contribute to liver injury in patients with and without preexisting liver disease.
Thieme. All rights reserved.
Medical:
Miscellaneous:
© Copyright 2026, Nutrition Evidence
We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.